Reuters logo
BRIEF-Oramed's ORMD-0901 safe and well tolerated in phase IB study
November 29, 2016 / 1:52 PM / in a year

BRIEF-Oramed's ORMD-0901 safe and well tolerated in phase IB study

Nov 29 (Reuters) - Oramed Pharmaceuticals Inc :

* Oramed’s ORMD-0901 (oral GLP-1 analog) found safe and well tolerated in phase IB study

* Oramed Pharmaceuticals Inc - “currently we are preparing to submit an IND with FDA and anticipate initiating a phase IIB study in 2017” Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below